About: Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.20 (-2.05%)
GERN NASDAQ Geron Corporation
Geron Corporation share price
GERN price activity
Last Price
$1.200
Change (24hr)
-0.03 USD (-2.05%)
Volume
2.51M
Volume (4w avg)
-
Open
$1.22
Day Range
$1.20 - $1.22
Previous Close
$1.22
Last Trade
13 Oct, 4:58 pm GMT+0
Delayed
13 Oct, 4:58 pm GMT+0
GERN price performance
Delayed
13 Oct, 4:58 pm GMT+0
GERN Market Signals